October 28, 2010

Canada Adds New Coumadin Alternative To Their Atrial Fibrillation Guidelines

Posted in Heart Disease in the News tagged , , , , , , , , , , , , at 1:47 am by keepyourhearthealthy

 

photo by Bill Longshaw

 

The newest anticoagulant drug Pradaxa (dabigatran) is already in Canada’s atrial fibrillation guidelines…even though it is still not approved to be sold in Canada!

Pradaxa (dabigatran) has made some huge headlines lately in the medical news ever since the FDA voted to approve it in September of this year.  Pradaxa is expected to be the first and only alternative to the super blood thinner Coumadin (warfarin).  For over 50 years people with atrial fibrillation have been forced to take Coumadin as a means of reducing their chances of stroke.  Coumadin requires frequent dose changes and blood checks to monitor the levels whereas Pradaxa does not.  (See previous article Coumadin and Warfarin Alternative Almost Here!)

In Canada, an update to their atrial fibrillation guidelines this week already includes recommendations for Pradaxa.  Surprisingly, Pradaxa is not even approved for market there yet!  It seems as though they have jumped the gun a bit but the authors are defending the update by saying it is “cutting edge.”  They apparently want to be prepared for the release of this promising new alternative drug.  Specifically, they recommend 150mg of Pradaxa to most patients in the future given that Pradaxa’s study showed this dose is more effective at preventing stroke than Coumadin.

The hype surrounding Pradaxa is certainly growing every day.  The manufacturer Boehringer Ingelheim has even started playing commercials here in the US.  Given that Pradaxa is not yet on pharmacy shelves, these commercials do not actually mention the drug name.  They simply offer to give more information about atrial fibrillation in general.  Since Boehringer Ingelheim is most well-known for its prostate drug Flomax, you can be certain the commercials are NOT a way to promote that medicine.  They are clearly gearing up their marketing for the highly anticipated Pradaxa.  And Canada is certainly rolling out the welcome mat!

Advertisements

1 Comment

  1. Bob said,

    I wish I had stock in Boehringer Ingelheim.


Comments are closed.

%d bloggers like this: